|
Roche's COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets accepting the CE mark
|
06 May 2020 |
|
Roche response to COVID-19 pandemic
|
26 March 2020 |
|
Roche initiates Phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia
|
20 March 2020 |
|
Roche's cobas SARS-CoV-2 Test to detect novel coronavirus receives FDA Emergency Use Authorization
|
16 March 2020 |
|
FDA accepts Roche’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer
|
27 February 2020 |
|
FDA grants priority review to Roche's Tecentriq monotherapy as first-line treatment of certain people with advanced non-small cell lung cancer
|
19 February 2020 |
|
Roche reports very strong results in 2019
|
03 February 2020 |
|
Roche and Illumina partner to broaden patient access to genomic testing
|
14 January 2020 |
|
Roche concludes acquisition of Spark Therapeutics, Inc. to strengthen presence in gene therapy
|
17 December 2019 |
|
Roche and Spark Therapeutics, Inc. announce extension of tender offer
|
09 December 2019 |
|
FDA grants priority review to Roche’s risdiplam for spinal muscular atrophy
|
27 November 2019 |
|
Roche presents new 6-year OCREVUS (ocrelizumab) data which showed that earlier initiation and continuation of treatment reduced disability progression in multiple sclerosis
|
13 September 2019 |
|
Roche presents new OCREVUS (ocrelizumab) biomarker data that increase understanding of disease progression in multiple sclerosis at ECTRIMS
|
10 September 2019 |
|
Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.
|
03 September 2019 |
|
Roche's first FDA-approved tumour-agnostic medicine
|
16 August 2019 |
|
Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.
|
01 August 2019 |
|
Japan becomes the first country to approve Roche's personalised medicine Rozlytrek
|
18 June 2019 |
|
FDA grants Roche's Polivy accelerated approval for people with previously treated aggressive lymphoma
|
13 June 2019 |
|
Roche's personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions in children and adolescents
|
20 May 2019 |
|
Roche reports a strong start in 2019 and raises the outlook for the full-year
|
18 April 2019 |